Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Impedimed Limited ( (AU:IPD) ) has provided an announcement.
ImpediMed Limited has released an investor presentation detailing its first half FY26 financial results to the market. The company advised that the presentation will be delivered to investors and confirmed the disclosure was approved for release by the chief executive officer, signalling a formal update to shareholders on recent performance and outlook.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited is an Australian medical technology company listed on the ASX under the ticker IPD. It develops and commercialises bioimpedance-based devices and related solutions, with a focus on clinical and diagnostic applications in healthcare markets.
YTD Price Performance: -50.0%
Average Trading Volume: 6,353,495
Technical Sentiment Signal: Sell
Current Market Cap: A$34.66M
For a thorough assessment of IPD stock, go to TipRanks’ Stock Analysis page.